v3.22.2.2

Segment Reporting (Tables) | 12 Months Ended
--- | ---
Jun. 30, 2022
Segment Reporting [Abstract] |
Schedule of Segment Reporting Information, by Segment | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Biopharmaceuticals |  | Bioprocessing |  | ​ |  | ​
Year Ended June 30, 2022 (in thousands) |  | iBio, Inc. |  | iBio CDMO |  | Eliminations |  | Total
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Revenues - external customers | ​ | $ | 1,884 | ​ | $ | 499 | ​ | $ | — | ​ | $ | 2,383
Revenues - intersegment | ​ | ​ | 1,586 | ​ | ​ | 2,455 | ​ | ​ | (4,041) | ​ | ​ | —
Cost of goods sold | ​ | ​ | — | ​ | ​ | 216 | ​ | ​ | — | ​ | ​ | 216
Gross profit | ​ | ​ | 3,470 | ​ | ​ | 2,739 | ​ | ​ | (4,041) | ​ | ​ | 2,167
Research and development | ​ |  | 11,819 | ​ | ​ | 8,260 | ​ | ​ | (2,350) | ​ |  | 17,729
General and administrative | ​ |  | 20,844 | ​ | ​ | 14,975 | ​ | ​ | (1,691) | ​ |  | 34,128
Operating loss | ​ |  | (29,194) | ​ | ​ | (20,496) | ​ | ​ | — | ​ |  | (49,690)
Interest expense | ​ |  | — | ​ | ​ | (1,412) | ​ | ​ | — | ​ |  | (1,412)
Forgiveness of note payable and accrued interest | ​ | ​ | — | ​ | ​ | 607 | ​ | ​ | — | ​ | ​ | 607
Interest and other income | ​ |  | 184 | ​ | ​ | 7 | ​ | ​ | — | ​ |  | 191
Consolidated net loss | ​ |  | (29,010) | ​ | ​ | (21,295) | ​ | ​ | — | ​ |  | (50,305)
Total assets | ​ |  | 156,893 | ​ | ​ | 43,092 | ​ | ​ | (100,578) | ​ |  | 99,407
Finance lease ROU assets | ​ |  | — | ​ | ​ | 74 | ​ | ​ | — | ​ |  | 74
Operating lease ROU assets | ​ | ​ | 3,068 | ​ | ​ | 1,952 | ​ | ​ | — | ​ | ​ | 5,020
Fixed assets, net of accumulated depreciation | ​ | ​ | 1,373 | ​ | ​ | 35,288 | ​ | ​ | — | ​ | ​ | 36,661
Intangible assets, net of accumulated amortization | ​ |  | 4,851 | ​ |  | — | ​ |  | — | ​ |  | 4,851
Amortization of ROU assets | ​ |  | — | ​ |  | 599 | ​ |  | — | ​ |  | 599
Depreciation expense | ​ |  | — | ​ |  | 2,275 | ​ |  | — | ​ |  | 2,275
Amortization of intangible assets | ​ | ​ | 401 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 401
​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Biopharmaceuticals | ​ | Bioprocessing | ​ | ​ | ​ | ​
Year Ended June 30, 2021 (in thousands) |  | iBio, Inc. | ​ | iBio CDMO | ​ | Eliminations | ​ | Total
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Revenues - external customers | ​ | $ | 1,098 | ​ | $ | 1,274 | ​ | $ | — | ​ | $ | 2,371
Revenues - intersegment | ​ | ​ | 1,017 | ​ | ​ | 1,307 | ​ | ​ | (2,324) | ​ | ​ | —
Cost of goods sold | ​ | ​ | 425 | ​ | ​ | 1,037 | ​ | ​ | — | ​ | ​ | 1,462
Gross profit | ​ | ​ | 1,690 | ​ | ​ | 1,543 | ​ | ​ | (2,324) | ​ | ​ | 909
Research and development | ​ |  | 2,960 | ​ |  | 8,370 | ​ |  | (1,341) | ​ |  | 9,989
General and administrative | ​ |  | 13,429 | ​ |  | 9,585 | ​ |  | (983) | ​ |  | 22,031
Operating loss | ​ |  | (14,699) | ​ |  | (16,412) | ​ |  | — | ​ |  | (31,111)
Interest expense | ​ |  | — | ​ |  | (2,454) | ​ |  | — | ​ |  | (2,454)
Settlement income | ​ | ​ | 10,200 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 10,200
Interest and royalty income | ​ |  | 151 | ​ |  | 1 | ​ |  | — | ​ |  | 152
Consolidated net loss | ​ |  | (4,349) | ​ |  | (18,864) | ​ |  | — | ​ |  | (23,213)
Total assets | ​ |  | 175,272 | ​ |  | 35,721 | ​ |  | (64,025) | ​ |  | 146,968
Finance lease ROU assets | ​ |  | — | ​ |  | 26,111 | ​ |  | — | ​ |  | 26,111
Fixed assets, net of accumulated depreciation | ​ | ​ | — | ​ | ​ | 8,628 | ​ | ​ | — | ​ | ​ | 8,628
Intangible assets, net of accumulated amortization | ​ | ​ | 952 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 952
Amortization of finance lease ROU assets | ​ |  | — | ​ |  | 1,651 | ​ |  | — | ​ |  | 1,651
Depreciation expense | ​ |  | — | ​ |  | 472 | ​ |  | — | ​ |  | 472
Amortization of intangible assets | ​ |  | 291 | ​ |  | — | ​ |  | — | ​ |  | 291

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration